Available Until 10/10/2023

ACCP/ASHP BCOP On-Demand Series: New Drugs, Publications, Indications, and Guideline Updates in Hematology/Oncology 2022 (Cert # L229133)

ACPE Numbers: 0217-9999-22-088-H01-P
Pre-Sale Date: 09/14/2022
Content Release Date: 10/12/2022
Expiration Dates: 10/10/2023
CE Credits: 1.5 (ACPE and BPS)
Activity Fee: $99 (ASHP member); $159 (non-member) 

Activity Overview

This recorded webinar series is part of the professional development program for the recertification of the BCOP pharmacist. 

This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. 

This online activity is approved for 1.5 hours of continuing pharmacy education credit and/or recertification credit.

This webinar covers key updates in hematology/oncology from 2022 including new drug approvals, new indications, withdrawal of indications, new clinical trials, and updates to the National Comprehensive Cancer Network guidelines for several cancer types.

The American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The target audience for this webinar is the pharmacist interested in learning more about updated information regarding oncologic management and/or treatment, and for Board-certified Oncology Pharmacists (BCOPs) looking to earn recertification credit.

Board certified pharmacists are eligible to receive up to 1.5 hours of recertification credit for completing this webinar. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment. 

This webinar is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/onc-review. 

These activities are part of the ACCP and ASHP professional development program for BCOP recertification approved by the BPS. 

For full program information, please visit: http://elearning.ashp.org/catalog/onc-recert

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

New Drugs, Publications, Indications, and Guideline Updates in Hematology/Oncology 2022




After participating in this CPE activity, learners should be able to:

  • Identify newly approved oncologic agents and new indications in hematology/oncology.
  • Review the pharmacology, dosing, and administration of newly approved oncologic agents.
  • Examine recent withdrawals of indications of medications in hematologic malignancies.
  • Evaluate recently published clinical trials likely to have a significant impact on solid tumors and hematologic malignancies.
  • Analyze key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for the treatment of various cancers.

Donald C. Moore, PharmD, FCCP, BCPS, BCOP, DPLA
Clinical Oncology Pharmacy Manager
Levine Cancer Institute, Atrium Health
Charlotte, NC

Courtney S. Watts Alexander, PharmD, BCPS, BCOP
Syeda Saba A Kareem, PharmD, BCOP

Janet Bramell, PharmD, BCPS, BCOP
Kelly Nystrom, PharmD, BCOP
Barbara Yim, PharmD, BCOP
Jeanne Noe, PharmD, BCOP
Carol Peek, PharmD, BCOP
Robert Luschen, PharmD, BCOP
Brenna Rowen, PharmD, BCOP

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ACCP and ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speaker’s bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identify and resolve conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Dr. Donald C. Moore: Advisory Board – Pfizer, AstraZeneca, Janssen, Oncopeptides

All other planners, presenters, reviewers, ASHP and ACCP, and others with an opportunity to control content report no financial relationships relevant to this activity.

This activity consists of audio and slides, an attestation statement, and an activity evaluation. Learners must review all content and complete the attestation statement and evaluation to receive continuing pharmacy education credit for the activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ACCP and ASHP.